NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

What Happened

• NeuroOne Medical Technologies Corporation filed an 8-K reporting results of its April 3, 2026 Annual Meeting. Stockholders approved a First Amendment to the company’s 2025 Equity Incentive Plan (Board adopted Feb 25, 2026), ratified its independent auditor, authorized a reverse stock split range, and elected two Class III directors.
• Key approvals included: an increase of 1,500,000 shares to the 2025 Equity Incentive Plan plus an automatic annual increase equal to 5% of Fully Diluted Shares on Jan 1 each year from 2027 through 2031 (Board may reduce any year’s increase prior to its effective date); a certificate amendment authorizing a reverse split of common stock at a ratio between 1-for-2 and 1-for-15 (final ratio to be set by the Board); and ratification of Baker Tilly US, LLP as independent registered public accounting firm.

Key Details

• Meeting turnout: 30,272,834 shares present (≈59.72% of outstanding common stock as of the record date).
• Equity plan amendment vote: For 15,146,194; Against 3,415,319; Abstain 318,056; Broker Non-Votes 11,393,265.
• Reverse split authorization vote: For 28,408,499; Against 1,780,031; Abstain 84,304. The Board will choose the exact split ratio within 1-for-2 to 1-for-15 if implemented.
• Director elections: Jeffrey Mathiesen — For 18,384,823, Withheld 494,745 (plus 11,393,266 broker non-votes); Edward Andrle — For 18,174,404, Withheld 705,164 (plus 11,393,266 broker non-votes).
• Auditor ratification: Baker Tilly US, LLP ratified with 30,031,054 votes for, 70,706 against, 171,074 abstain.

Why It Matters

• The equity plan increase and automatic annual refresh could enable additional stock-based awards, which may increase share dilution over time as awards are granted. Investors should monitor future grant activity and filings showing issuance under the amended plan.
• The authorized reverse stock split (1-for-2 to 1-for-15) gives the Board flexibility to consolidate shares; if implemented, a reverse split will reduce the number of outstanding shares and increase the per-share price proportionally, which can affect trading liquidity and market metrics. The company must file an 8-K when/if the Board implements the split with the chosen ratio.
• Re-election of directors and ratification of the auditor maintain current governance and oversight. Investors should watch for follow-up disclosures on implementation details for the reverse split and any future equity awards under the amended plan.